✨
AI Summary
- Top-selling drugs of 2023 and the impact of the COVID cliff are analyzed.
- Roche reassesses priorities due to falling sales; Sanofi reports an immunology win.
- BMS showcases a strong pipeline; potential acquisition targets are identified.